Emd Serono Research & Development Institute, Inc.

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This early-stage study tests two drugs, avelumab and lenvatinib, together in children with certain brain tumors. The goal is to find safe doses and see if the combination can slow tumor growth. The study involves 17 children whose tumors have worsened after prior treatment.

This early-stage study tests a new drug called tuvusertib, alone or with another drug (niraparib), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see how the drug works in the …

This study tested a combination of two targeted drugs, tepotinib and osimertinib, in people with advanced non-small cell lung cancer whose tumors had a specific genetic change (MET amplification) and had stopped responding to the standard treatment osimertinib. The goal was to se…

This study tests whether combining avelumab with other anti-cancer drugs can keep advanced bladder cancer from growing after initial chemotherapy. About 256 adults with bladder cancer that did not worsen after first-line chemo will receive one of several drug combinations as main…

This early-phase study tests a new drug called M9466, which blocks a protein (PARP1) that helps cancer cells repair themselves. The goal is to see if it is safe and tolerable when given alone or with other drugs (tuvusertib or an ARPi) in people with advanced solid tumors that ha…

This study tests a combination of two drugs, tuvusertib and cemiplimab, in people with a type of lung cancer (non-squamous non-small cell) that has worsened after standard treatments like immunotherapy and chemotherapy. The goal is to see if the combination can shrink tumors or s…

This early-phase study tests a new drug called tuvusertib combined with other cancer treatments in people with advanced solid tumors that have stopped responding to standard therapy. The main goals are to find safe doses and understand side effects. About 120 adults with various …

This study tested the drug tepotinib in 337 adults with advanced lung cancer that has specific changes in the MET gene. The goal was to see if the drug could shrink or stop the growth of tumors. Participants took tepotinib pills, and researchers measured how many people had their…

This study tests two new drug combinations for people with a type of ovarian cancer that has stopped responding to a standard treatment called PARP inhibitors. The trial involves 63 participants and aims to see if the new combinations can shrink or control the tumor. The goal is …